133 related articles for article (PubMed ID: 2820199)
1. Binding and degradation of vasoactive intestinal peptide in prolactin-producing cultured rat pituitary tumour cells (GH4C1).
Bjøro T; Wiik P; Opstad PK; Gautvik KM; Haug E
Acta Physiol Scand; 1987 Aug; 130(4):609-18. PubMed ID: 2820199
[TBL] [Abstract][Full Text] [Related]
2. Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes.
Wanke IE; Rorstad OP
Endocrinology; 1990 Apr; 126(4):1981-8. PubMed ID: 2156675
[TBL] [Abstract][Full Text] [Related]
3. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
4. VIP receptor subtypes in mouse cerebral cortex: evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes.
Martin JL; Feinstein DL; Yu N; Sorg O; Rossier C; Magistretti PJ
Brain Res; 1992 Jul; 587(1):1-12. PubMed ID: 1326373
[TBL] [Abstract][Full Text] [Related]
5. Characterization and solubilization of vasoactive intestinal peptide receptors from rat lung membranes.
Provow S; Veliçelebi G
Endocrinology; 1987 Jun; 120(6):2442-52. PubMed ID: 3032591
[TBL] [Abstract][Full Text] [Related]
6. [Autoradiographic localization and characterization of the ocular binding sites of the VIP (vasoactive intestinal peptide) in albino rats and rabbits].
Denis P; Dussaillant M; Elena PP; Nordmann JP; Rostene W; Laroche L
Ophtalmologie; 1990; 4(1):30-2. PubMed ID: 2174530
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin inhibits prolactin secretion by multiple mechanisms involving a site of action distal to increased cyclic adenosine 3',5'-monophosphate and elevated cytosolic Ca2+ in rat lactotrophs.
Bjøro T; Ostberg BC; Sand O; Torjesen PA; Penman E; Gordeladze JO; Iversen JG; Gautvik KM; Haug E
Acta Physiol Scand; 1988 Jul; 133(3):271-82. PubMed ID: 2906508
[TBL] [Abstract][Full Text] [Related]
8. Distribution of vasoactive intestinal polypeptide (VIP) binding in circular muscle and characterization of VIP binding in canine small intestinal mucosa.
Mao YK; Barnett W; Coy DH; Tougas G; Daniel EE
J Pharmacol Exp Ther; 1991 Sep; 258(3):986-91. PubMed ID: 1653848
[TBL] [Abstract][Full Text] [Related]
9. The influences of GnRH, oxytocin and vasoactive intestinal peptide on LH and PRL secretion by porcine pituitary cells in vitro.
Bogacka I; Siawrys G; Okrasa S; Kaminski T; Przala J
J Physiol Pharmacol; 2002 Sep; 53(3):439-51. PubMed ID: 12369740
[TBL] [Abstract][Full Text] [Related]
10. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells.
Hohmann EL; Tashjian AH
Endocrinology; 1984 Apr; 114(4):1321-7. PubMed ID: 6323142
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
Couvineau A; Rousset M; Laburthe M
Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
13. Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung.
Carstairs JR; Barnes PJ
J Pharmacol Exp Ther; 1986 Oct; 239(1):249-55. PubMed ID: 3020233
[TBL] [Abstract][Full Text] [Related]
14. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J
Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330
[TBL] [Abstract][Full Text] [Related]
15. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells.
Frucht H; Gazdar AF; Park JA; Oie H; Jensen RT
Cancer Res; 1992 Mar; 52(5):1114-22. PubMed ID: 1310640
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+.
Bjøro T; Ostberg BC; Sand O; Gordeladze J; Iversen JG; Torjesen PA; Gautvik KM; Haug E
Mol Cell Endocrinol; 1987 Feb; 49(2-3):119-28. PubMed ID: 2435588
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous solubilization of high-affinity receptors for VIP and glucagon and of a low-affinity binding protein for VIP, shown to be identical to calmodulin.
Andersson M; Carlquist M; Maletti M; Marie JC
FEBS Lett; 1993 Feb; 318(1):35-40. PubMed ID: 8382169
[TBL] [Abstract][Full Text] [Related]
18. Solubilization of rat lung vasoactive intestinal peptide receptors in the active state. Characterization of the binding properties and comparison with membrane-bound receptors.
Patthi S; Simerson S; Veliçelebi G
J Biol Chem; 1988 Dec; 263(36):19363-9. PubMed ID: 2848823
[TBL] [Abstract][Full Text] [Related]
19. Characterization and localization of vasoactive intestinal peptide receptors in the rat lung.
Leroux P; Vaudry H; Fournier A; St-Pierre S; Pelletier G
Endocrinology; 1984 May; 114(5):1506-12. PubMed ID: 6325122
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and molecular identification of vasoactive intestinal peptide (VIP) receptors in normal and cancerous gastric mucosa in man.
Gespach C; Bawab W; Chastre E; Emami S; Yanaihara N; Rosselin G
Biochem Biophys Res Commun; 1988 Mar; 151(2):939-47. PubMed ID: 2831906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
